

Targeted Disruption of the *MyD88* Gene Results in Loss of IL-1- and IL-18-Mediated Function

Osamu Adachi,^{*†§} Taro Kawai,^{*§}
Kiyoshi Takeda,^{*§} Makoto Matsumoto,^{*§}
Hiroko Tsutsui,^{‡§} Masafumi Sakagami,[†]
Kenji Nakanishi,^{‡§} and Shizuo Akira^{*§||}

^{*}Department of Biochemistry

[†]Department of Otolaryngology

[‡]Department of Immunology and Medical Zoology

Hyogo College of Medicine

1-1 Mukogawa-cho, Nishinomiya

Hyogo 663-8501

Japan

[§]Core Research for Evolutional Science and Technology
Japan Science and Technology Corporation

Summary

MyD88, originally isolated as a myeloid differentiation primary response gene, is shown to act as an adaptor in interleukin-1 (IL-1) signaling by interacting with both the IL-1 receptor complex and IL-1 receptor-associated kinase (IRAK). Mice generated by gene targeting to lack *MyD88* have defects in T cell proliferation as well as induction of acute phase proteins and cytokines in response to IL-1. Increases in interferon- γ production and natural killer cell activity in response to IL-18 are abrogated. In vivo Th1 response is also impaired. Furthermore, IL-18-induced activation of NF- κ B and c-Jun N-terminal kinase (JNK) is blocked in *MyD88*^{-/-} Th1-developing cells. Taken together, these results demonstrate that *MyD88* is a critical component in the signaling cascade that is mediated by IL-1 receptor as well as IL-18 receptor.

Introduction

Interleukin-1 (IL-1) is a proinflammatory cytokine involved in local and systemic inflammatory reaction (reviewed by Dinarello, 1989, 1996). IL-1 induces a variety of inflammatory proteins, such as acute phase proteins, cytokines, and adhesion molecules, whose genes are mainly regulated by NF- κ B and/or AP-1 (reviewed by Dinarello, 1989, 1996). IL-1 signaling is initiated by the formation of the high-affinity complex composed of IL-1, IL-1 receptor (IL-1R), and IL-1R accessory protein (IL-1R-AcP). This is followed by the recruitment of IL-1 receptor-associated kinase (IRAK) to the receptor complex (Greenfeder et al., 1995; Cao et al., 1996a; Huang et al., 1997; Korherr et al., 1997; Wesche et al., 1997a). Then, IRAK leaves the receptor complex and interacts with TRAF6, which finally results in NF- κ B activation (Cao et al., 1996b). IL-18, originally identified as an interferon- γ (IFN γ)-inducing factor, promotes the production of IFN γ and enhances natural killer cell activity (Okamura et al., 1995a, 1995b). IL-18 synergizes with IL-12 in inducing IFN γ production from T cells and plays an important role in Th1 response (Robinson et al., 1997; Takeda

et al., 1998). Despite the functional similarity, IL-18 is not structurally related to IL-12. IL-18 has a structural similarity with IL-1 (Bazan et al., 1996). IL-18 is synthesized as an inactive precursor that requires cleavage by IL-1 β -converting enzyme (ICE)/caspase 1 for its maturation, as in the case of IL-1 β (Ghayur et al., 1997; Gu et al., 1997). IL-18 also activates IRAK and NF- κ B (Matsumoto et al., 1997; Robinson et al., 1997).

The Toll protein determines dorsal-ventral polarity in *Drosophila melanogaster* embryos and also participates in an anti-fungal immune response (Hashimoto et al., 1988; Morisato and Anderson, 1994, 1995; Lemaitre et al., 1996). The cytoplasmic domain of Toll is homologous to that of IL-1R (Gay and Keith, 1991). The signaling pathway through Toll in *Drosophila* shows striking structural and functional similarities with the signaling pathway induced by the IL-1Rs in mammals (Wasserman, 1993; Belvin and Anderson, 1996). Toll activates the transcription factor Dorsal, a *Drosophila* homolog of NF- κ B, upon binding to its ligand Spatzle (Morisato and Anderson, 1994, 1995). Transduction of the intracellular signal generated by Toll requires the adaptor molecule called Tube for the association of Toll with the Pelle protein kinase, a *Drosophila* homolog of IRAK (Letsou et al., 1993; Shelton and Wasserman, 1993; Grosshans et al., 1994; Galindo et al., 1995; Norris and Manley, 1996). Until recently, a mammalian homolog of Tube had not been identified.

MyD88 was originally isolated as a myeloid differentiation primary response gene, which is rapidly induced upon IL-6-stimulated differentiation to macrophages in M1 myeloleukemic cells (Lord et al., 1990). This immediate-early activation profile suggested that *MyD88* functions in the regulated progression of myeloid differentiation. *MyD88* is subsequently found to be related to the IL-1R family, particularly Toll (Hultmark, 1994; Hardiman et al., 1996; Bonnert et al., 1997). Different from the IL-1R family, *MyD88* does not harbor the transmembrane portion. The death domain is present in its N terminus. The C-terminal domain of the protein is highly homologous to the cytoplasmic segments of the IL-1R family. Recently, *MyD88* has been cloned as an adaptor molecule that recruits IRAK to the IL-1R complex after IL-1 stimulation and activates NF- κ B (Muzio et al., 1997; Wesche et al., 1997b). *MyD88* is therefore a functional homolog of Tube, although these two molecules are not structurally related. To know the in vivo functional role of *MyD88* in IL-1 as well as IL-18 signaling, we have generated *MyD88*-deficient mice. In *MyD88*-deficient mice, all of the IL-1- and IL-18-mediated functions examined were impaired, demonstrating that *MyD88* is a functional molecule critical for IL-1- and IL-18-mediated signaling.

Results and Discussion

Generation of *MyD88*-Deficient Mice

The mouse *MyD88* gene was disrupted by homologous recombination in E14.1 embryonic stem (ES) cells. A targeting vector was designed to replace two exons

|| To whom correspondence should be addressed (e-mail: akira@hyo-med.ac.jp).




Figure 1. Targeted Disruption of the Mouse *MyD88* Gene

(A) Maps of the *MyD88* wild-type genome, targeting vector, and predicted targeted gene. Open and closed boxes denote the noncoding and coding exons, respectively. Restriction enzymes: B, BamHI; P, PstI.

(B) Southern blot analysis of offspring from the heterozygote intercrosses. Genomic DNA was extracted from mouse tails, digested with BamHI, electrophoresed, and hybridized with the probe indicated in (A). The approximate size of the wild-type band is 4.3 kb, and the mutated band is 1.9 kb.

(C) Northern blot analysis of liver cells. Total RNA was extracted from liver, electrophoresed, transferred to nylon membrane, and hybridized with the mouse *MyD88* cDNA probe. The same membrane was rehybridized with a β -actin probe.

encoding the C-terminal portion of *MyD88* with the neomycin resistance gene (Figure 1A). This region of the *MyD88* gene shows high similarity with the cytoplasmic domain of the IL-1R. The corresponding region in the human IL-1R includes the residues critical for its signaling (Hultmark, 1994; Hardiman et al., 1996; Bonnert et al., 1997). Homologous recombination was achieved in 33 out of 176 ES cell clones doubly resistant to G418 and gancyclovir. Three targeted ES cell clones were microinjected into C57BL/6 blastocysts, two of which successfully transmitted the disrupted *MyD88* gene through the germline (Figure 1B). *MyD88*-deficient (*MyD88*^{-/-}) mice were born at the expected Mendelian ratios (+/+ : +/- : -/- = 52: 93: 53). The mice grew healthy and showed no obvious abnormalities until 20 weeks of age. We performed Northern blot analysis to confirm that the mutation causes inactivation of the *MyD88* gene. *MyD88* mRNA could not be detected in the liver and spleen of *MyD88*^{-/-} mice (Figure 1C). Flow cytometric analysis of the expression of CD3, B220, CD4, and CD8 in thymus, spleen, and lymph node showed that lymphocyte composition was not altered in *MyD88*^{-/-} mice when compared with wild-type mice (data not shown).

Impaired IL-1-Mediated Functions in *MyD88*^{-/-} Mice

We first examined IL-1-mediated response in the mice. IL-1 is shown to be a costimulant for T cell growth (Mannel et al., 1985; Dinarello, 1989; Suda et al., 1989). Thymocytes of *MyD88*^{-/-} mice and their wild-type littermate controls were cultured with IL-1 β plus several stimuli. In wild-type mice, thymocytes displayed enhanced proliferation when cultured with phytohemagglutinin (PHA), concanavalin A (ConA), or a low concentration of IL-2 in the presence of IL-1 β . However, *MyD88*^{-/-} thymocytes did not show any enhanced proliferation in response to IL-1 β (Figure 2). Similarly, splenocytes from *MyD88*^{-/-} mice did not proliferate in response to IL-1 β (data not shown). Thymocytes from wild-type and *MyD88*^{-/-} mice showed almost equal proliferative response to IL-2 plus Phorbol 12-Myristate 13-Acetate (PMA) or IL-2 plus ConA, indicating that IL-1-mediated

growth signal was specifically impaired in the lymphocytes from *MyD88*^{-/-} mice (Figure 2).

IL-1 is also shown to induce production of acute phase proteins and inflammatory cytokines such as TNF- α and IL-6. We next analyzed the effect of *MyD88* deficiency on these functions. Mice were intravenously injected with 1 μ g of IL-1 β , and 2 hr later liver and sera were taken. Total RNA was extracted from the liver and subjected to Northern blot analysis for expression of serum amyloid A (SAA-I), serum amyloid P (SAP), and haptoglobin (HP). In wild-type mice, there was a dramatic increase in mRNA expression for SAA-I, SAP, and HP after IL-1 β injection (Figure 3A). However, IL-1-induced increase in mRNA expression of SAA-I, SAP, or HP was not observed in *MyD88*^{-/-} mice. Serum concentrations of TNF- α and IL-6 were measured by enzyme-linked immunosorbent assay (ELISA). Serum TNF- α and IL-6 concentrations were significantly increased after IL-1 β injection in wild-type mice (Figure 3B). In contrast, neither serum TNF- α nor IL-6 level was elevated after IL-1 β treatment in *MyD88*^{-/-} mice. Thus, IL-1-mediated




Figure 2. Impaired IL-1-Mediated T Cell Proliferation in *MyD88*^{-/-} Mice

Thymocytes from wild-type and *MyD88*^{-/-} mice were incubated with 100 U/ml IL-1 β in the presence of the indicated mitogens for 72 hr. [³H]thymidine was pulsed for the last 12 hr, and [³H] uptake was measured. Thymocytes were also incubated with 20 ng/ml IL-2 in the presence of 10 ng/ml PMA or 2.5 μ g/ml ConA for 72 hr. [³H] uptake was measured. Representative from three independent experiments.




Figure 3. Impaired IL-1-Induced Expression of Acute Phase Proteins and Production of Inflammatory Cytokines in MyD88^{-/-} Mice (A) Mice were intravenously injected with IL-1 β . Total RNA was extracted from liver after 2 hr of injection and subjected to Northern blot analysis using probes for acute phase proteins such as SAA-I, SAP, and HP. The figure is the representative of results from three independent experiments. (B) Mice were intravenously injected with 1 μ g of IL-1 β . Sera were taken 2 hr after injection. Concentration of TNF- α and IL-6 was measured by ELISA. The data are mean \pm S.D. of six serum samples. N.D., not detected.

major biological functions were severely impaired in MyD88^{-/-} mice.

Impaired IL-18-Mediated Functions in MyD88^{-/-} Mice

IL-18, originally identified as an IFN γ -inducing factor, has a structural similarity to IL-1, and the receptor for IL-18 belongs to the IL-1R family (Okamura et al., 1995a, 1995b; Bazan et al., 1996; Parnet et al., 1996; Torigoe et al., 1997). Therefore, we examined IL-18-mediated biological functions in MyD88^{-/-} mice. IL-18 has been shown to be a potent activator of natural killer (NK) cells (Okamura et al., 1995a, 1995b; Tsutsui et al., 1996; Ushio et al., 1996). Splenocytes were cultured in the presence or absence of IL-18 for 24 hr, and NK lytic activity was analyzed by ⁵¹Cr release from YAC-1 target cells. In vitro culture of splenocytes with IL-18 dramatically enhanced the lytic activity against YAC-1 cells in wild-type mice (Figure 4A). However, IL-18 did not enhance NK lytic

activity in MyD88^{-/-} mice. Stimulation of splenocytes with IL-2 led to almost equal augmentation of the NK lytic activity against YAC-1 cells in both wild-type and MyD88^{-/-} mice, indicating that IL-18-mediated activation of NK cells was specifically disturbed in MyD88^{-/-} mice (Figure 4A). Besides the activation of NK cells, in vitro stimulation of splenocytes with IL-18 induced IFN γ production in wild-type mice (Figure 4B). In contrast, IFN γ production in response to IL-18 was not observed in MyD88^{-/-} mice (Figure 4B). When wild-type mice were treated with anti-asialo GM1 antibody, which reduces NK cell population in vivo, splenocytes did not produce IFN γ in response to IL-18 (data not shown). These data suggest that NK cells in MyD88^{-/-} mice have a defect in their capacity to promote IFN γ production in response to IL-18.

Additionally, IL-18 has been recently shown not to drive Th1 development but to potentiate IL-12-induced Th1 development (Matsui et al., 1997; Robinson et al., 1997; Takeda et al., 1998). Naive splenic T cells were cultured with IL-12 on anti-CD3 antibody-coated plates to induce Th1 cell development. After 4 days of culture, these Th1-developing cells were washed and restimulated with IL-18 or IL-12 on anti-CD3 antibody-coated plates for 24 hr. Culture supernatants were analyzed for IFN γ production by ELISA. Both wild-type and MyD88^{-/-} T cells produced almost equal levels of IFN γ by stimulation with anti-CD3 antibody, indicating that IL-12-induced Th1 cell development in vitro was not impaired in MyD88^{-/-} mice. T cells from wild-type mice produced an elevated level of IFN γ in response to IL-18 (Figure 5A). In contrast, T cells from MyD88^{-/-} mice did not show any enhanced production of IFN γ in response to IL-18.

It has been shown that IL-18-deficient mice displayed defective Th1 cell development after injection of *Propionibacterium acnes* (*P. acnes*) and *Bacillus Calmette-Guérin* (BCG) (Takeda et al., 1998). MyD88^{-/-} mice were injected with heat-killed *P. acnes*, and 7 days later splenic T cells were purified and stimulated with immobilized anti-CD3 antibody in the presence or absence of IL-18. Wild-type T cells produced significant levels of IFN γ , and the presence of IL-18 resulted in enhanced production of IFN γ . In contrast, IFN γ production from MyD88^{-/-} T cells was severely reduced when compared with wild-type. In addition, increased IFN γ production in response to IL-18 was not observed in MyD88^{-/-} T cells (Figure 5B). T cells of BCG-infected wild-type mice also produced high amounts of IFN γ and more enhanced




Figure 4. Impaired IL-18-Mediated NK Cell Activation in MyD88^{-/-} Mice (A) Splenocytes from wild-type and MyD88^{-/-} mice were cultured in the presence of IL-18 or IL-2 for 24 hr. NK lytic activity against YAC-1 target cells was analyzed. Representative results from three independent experiments. (B) Splenocytes were cultured with or without 20 ng/ml IL-18 for 24 hr. Concentration of IFN γ in the culture supernatants was measured by ELISA. N.D., not detected.




Figure 5. Impaired IL-18-Mediated Th1 Response in MyD88^{-/-} Mice (A) Splenic T cells were purified and incubated with or without 2 ng/ml IL-12 on anti-CD3 Ab-coated plates. After 4 days of culture, T cells were washed and restimulated with 20 ng/ml IL-18 and/or 2 ng/ml IL-12 on anti-CD3 Ab-coated plates for 24 hr. Production of IFN γ from T cells was analyzed by ELISA. (B) Mice were intraperitoneally injected with 500 μ g of heat-killed *P. acnes*. Seven days after injection, splenic T cells were purified and stimulated with immobilized anti-CD3 antibody in the presence or absence of 20 ng/ml IL-18 for 24 hr. The concentration of IFN γ in culture supernatants was measured by ELISA. In the case of BCG infection, mice were intravenously injected with 2 mg of BCG. Production of IFN γ from splenic T cells was analyzed by ELISA 14 days later.

levels of IFN γ in response to IL-18. However, IFN γ production from T cells of BCG-infected MyD88^{-/-} mice was about 3-fold lower than that from wild-type T cells (Figure 5B). These results demonstrate that MyD88^{-/-} mice are defective in Th1 cell development in vivo as is

the case with IL-18-deficient mice. Thus, major biological activities mediated by IL-18 were completely abolished in MyD88^{-/-} mice.

Dominant Negative MyD88 Blocks IL-18-Induced Activation of NF- κ B and AP-1

MyD88^{-/-} mice displayed severely impaired IL-18-mediated functions. Therefore, we examined whether the IL-18R complex interacts with MyD88 as shown in the case of the IL-1R complex (Muzio et al., 1997; Wesche et al., 1997b). We transiently coexpressed FLAG-tagged MyD88 and Myc-tagged IL-18R into COS-7 cells. The cell lysates were immunoprecipitated with the anti-Myc antibody and blotted with the anti-FLAG antibody. FLAG-tagged MyD88 was coimmunoprecipitated with the anti-Myc antibody (Figure 6A). Reciprocally, Myc-tagged IL-18R was also coimmunoprecipitated with the anti-FLAG antibody. Thus, MyD88 specifically associates with IL-18R.

The C-terminal domain of MyD88 (amino acids 152 to 296) has been shown to act as a dominant negative inhibitor of IL-1R complex-induced NF- κ B activation (Muzio et al., 1997; Wesche et al., 1997b). In addition, IL-18 is shown to induce NF- κ B activation as does IL-1 (Matsumoto et al., 1997; Robinson et al., 1997). Therefore, we studied whether the dominant negative MyD88 mutant blocks IL-18-induced NF- κ B activation as well. COS-7 cells were transiently transfected with MyD88 (152–296) expression vector together with NF- κ B-dependent luciferase reporter gene, and luciferase activity after IL-18 treatment was measured. Coexpression of MyD88 (152–296) almost completely blocked IL-18-induced NF- κ B activation (Figure 6B, upper). IL-18 is also shown to activate AP-1-dependent gene expression (Barbulescu et al., 1998). We examined whether MyD88 (152–296) also acts as a dominant negative mutant of IL-18-induced AP-1 activation. Stimulation with IL-18 induced an approximately 3- to 4-fold increase in AP-1 activity, and this activation was blocked by coexpression of MyD88 (152–296) (Figure 6B, lower). Taken together, these results show that MyD88 is involved in IL-18-induced activation of both NF- κ B and AP-1.




Figure 6. MyD88 Interacts with IL-18 Receptor and Induces NF- κ B and AP-1 Activation

(A) COS-7 cells were transiently cotransfected with the indicated combination of expression vectors for FLAG-tagged MyD88, Myc-tagged IL-18R, or empty vector (Vector). After 36 hr, cell lysates were prepared and immunoprecipitated with either anti-Myc antibody or anti-FLAG antibody. Coprecipitating FLAG-MyD88 or Myc-IL-18R protein was detected by Western blotting with either anti-FLAG antibody or anti-Myc antibody, respectively. The total level of protein expression was monitored by Western blot analysis of the same lysates with the relevant antibodies. The molecular weight (in kilodaltons) is listed on the left.

(B) COS-7 cells were transiently cotransfected with pNF- κ B-Luc or pAP-1-Luc reporter gene plasmid together with expression plasmid for IL-18R or MyD88 (152–296) as

indicated. Cells were left untreated (open bars) or stimulated with 1.0 μ g/ml IL-18 (closed bars) 24 hr after transfection. After 3 hr, relative luciferase activity was determined. Similar results were obtained from three independent experiments.




Figure 7. Loss of NF- κ B and JNK Activation in Response to IL-18 in MyD88^{-/-} Cells

(A) T cells cultured with IL-12 plus anti-CD3 antibody for 4 days were stimulated with 100 ng/ml IL-18 for 30 min, and thymocytes were stimulated with 100 ng/ml TNF- α for 30 min. Nuclear extracts were then prepared and incubated with a specific probe containing NF- κ B-binding sites, and NF- κ B activity was determined by a gel mobility shift assay. Specificity was determined by adding none (N), 50-fold molar excess of specific competitor (C), or 1.0 μ g of specific antibody to p65 (Ab). Inducible NF- κ B complex was indicated by the arrow. The asterisks show the supershift. The free probe was indicated by the arrow head.

(B) Cells (Th1-developing cells used for IL-18 stimulation and thymocytes for TNF- α) were left untreated or stimulated with 100 ng/ml IL-18 or 100 ng/ml TNF- α for 20 min. Cell lysates were prepared and immunoprecipitated with anti-JNK antibody. The kinase activity was measured using GST-c-Jun-fusion protein as a substrate (upper). The lower panels show Western blot analysis of the same lysates with anti-JNK antibody.

Loss of IL-18-Induced NF- κ B DNA Binding Activity and JNK Activation in MyD88^{-/-} Th1-Developing Cells

We next investigated whether IL-18-induced activation of NF- κ B was observed in MyD88^{-/-} cells. Splenic T cells cultured with IL-12 plus anti-CD3 antibody for 4 days were starved for 3 hr and then stimulated with IL-18. Nuclear extracts from the stimulated cells were analyzed by a gel mobility shift assay using a specific probe containing NF- κ B binding site. As shown in Figure 7A, IL-18-induced NF- κ B DNA binding activity was detected in the nuclear extracts from wild-type cells but not from MyD88^{-/-} cells. On the other hand, treatment of wild-type or MyD88^{-/-} thymocytes with TNF- α resulted in almost the same levels of NF- κ B DNA binding activity, demonstrating that the impaired IL-18-induced NF- κ B activation in MyD88^{-/-} cells was not due to the abnormal function or down-regulation of NF- κ B.

In addition to induction of NF- κ B activation, IL-1 is also shown to activate c-Jun N-terminal kinase (JNK) (Wesche et al., 1997a). To test whether IL-18 induces JNK activation, we carried out an in vitro kinase assay using GST-c-Jun-fusion protein as a substrate (Figure 7B). Treatment with IL-18 induced JNK activation in

Th1-developing cells of wild-type mice. However, IL-18-induced JNK activation was not observed in MyD88^{-/-} cells. By contrast, normal activation of JNK was observed in MyD88^{-/-} cells treated with TNF- α . Thus, IL-18-induced NF- κ B and JNK activation was abrogated in MyD88^{-/-} mice, although TNF- α -induced activation was not affected. Taken together, these results demonstrate that MyD88 is essential for IL-18-induced activation of both NF- κ B and JNK.

In the present study, we demonstrated that MyD88 is essential for IL-1 and IL-18 signaling, because the major functions mediated by these cytokines were almost completely abolished in the MyD88^{-/-} mice. The family of IL-1R/Toll related proteins is now expanding in mammals (Medzhitov and Janeway, 1997; Medzhitov et al., 1997). These include IL-1R-related protein (IL-1Rrp), IL-1Rrp2, T1/ST2, and recently identified human Toll-like molecules (TLR1-5) (Yanagisawa et al., 1993; Lovenberg et al., 1996; Mitcham et al., 1996; Parnet et al., 1996; Rock et al., 1998). Recently, IL-1Rrp was found to be the receptor for IL-18 (Torigoe et al., 1997). The ligands and biological functions of several IL-1R-related molecules have yet to be clarified. MyD88 may also participate in the signaling of these orphan receptors such as IL-1Rrp2, T1/ST2, and TLR1-5. Thus, the use of MyD88^{-/-} mice may help to elucidate the functions of these orphan receptors. In this respect, it is noteworthy that MyD88^{-/-} mice are viable when we consider that the Toll pathway in *Drosophila* is analogous to the IL-1 pathway in mammals and that MyD88 is a functional mammalian homolog of *Drosophila* Tube, whose loss of function results in early embryonic lethality due to defective dorsoventral polarity in *Drosophila* (Letsou et al., 1993; Belvin and Anderson, 1996; Norris and Manley, 1996). Based on these findings, mammalian Toll-like molecules appear to utilize another Tube-related molecule or do not play a major role in mammalian development. Future studies will be required to answer this question. Finally, agents that block the function of MyD88 will be therapeutically useful against a variety of pathological conditions associated with excessive production of the IL-1 family of cytokines.

Experimental Procedures

Generation of MyD88^{-/-} Mice

The MyD88 genomic DNA was screened from a 129/SvJ mouse genomic library (Stratagene), subcloned into pBluescript vector (Stratagene), and characterized by restriction enzyme mapping and DNA sequencing. A targeting vector was constructed to replace the 1.0 kb genomic fragment with the neomycin resistance gene from pMC1-neo (Stratagene). The replaced genomic fragment contained 2 exons encoding the domain that resembles the cytoplasmic domain of the IL-1RACp. The neomycin resistance gene was flanked by the 1.1 kb 5' genomic fragment and the 5.2 kb 3' fragment. An HSV-tk cassette was introduced at the 3' end of the genomic fragment. E14.1 ES cells were transfected with the linearized targeting vector and selected with G418 and gancyclovir. Doubly resistant clones were screened for homologous recombination by PCR and verified by Southern blot analysis using the probe indicated in Figure 1A. Three independently identified targeted ES clones were microinjected into the blastocysts of C57BL/6 mice. Chimeric mice were mated with C57BL/6 female mice to produce heterozygous mice. Heterozygous mice were intercrossed to obtain homozygotes. MyD88^{-/-} mice and their wild-type littermates from these intercrosses were used for experiments.

T Cell Proliferation Assay

Thymocytes (1×10^6) were cultured in 96-well plates for 72 hr with 100 U/ml IL-1 β (Genzyme) in the presence of 2 μ g/ml PHA, 2.5 μ g/ml ConA, or 2 ng/ml IL-2. [3 H]thymidine was pulsed for the last 12 hr, and [3 H] uptake was measured. In the case of the response to IL-2, thymocytes were cultured with 20 ng/ml IL-2 (Genzyme) in the presence of 10 ng/ml PMA or 2.5 μ g/ml ConA.

Induction of Inflammatory Cytokines and Acute Phase Proteins

Mice were intravenously injected with 1 μ g of recombinant mouse IL-1 β (Genzyme). After 2 hr of injection, mice were bled for serum cytokine and sacrificed. Total RNA was extracted from the liver using the TRIZOL reagent (GIBCO). RNA (10 μ g) was electrophoresed, transferred to a nylon membrane, and hybridized with 32 P-labeled cDNA probes for SAA-I, SAP, and HP. Serum concentrations of TNF- α and IL-6 were determined by ELISA (Genzyme).

Analysis of NK Cell Activity

Splenocytes were cultured for 24 hr with or without 20 ng/ml IL-18 or 100 U/ml IL-2. Then, cultured cells were incubated with 51 Cr-labeled YAC-1 target cells at the indicated effector/target ratios. After 4 hr of incubation, supernatants were counted for 51 Cr release using a gamma counter. IL-18 was kindly provided by Hayashibara Biochemical Laboratories, Inc. (Japan).

Induction of Th1 Cell Differentiation

Splenic T cells were purified as described previously (Takeda et al., 1998). In brief, splenic T cells were enriched by two rounds of nylon wool column passage. Enriched T cells were incubated with anti-I-A b antibody for 30 min on ice and then washed and incubated with rabbit complement (Low-Tox-M, Cedar Lane) for 45 min at 37°C. Cell purity was analyzed by flow cytometry using fluorescein isothiocyanate-conjugated anti-CD3 antibody (PharMingen). T cells purified to more than 95% were cultured on anti-CD3 Ab (20 μ g/ml)-coated plates in the presence of 2 ng/ml IL-12. After the 4 days of culture, cells were harvested and washed with Hanks' balanced salt solution. Cells (2×10^6) were stimulated on anti-CD3 Ab (20 μ g/ml)-coated 96-well plates for 24 hr in the presence or absence of 20 ng/ml IL-18 and/or 2 ng/ml IL-12. Concentration of IFN γ in culture supernatants was determined by ELISA (Genzyme).

In the case of *in vivo* induction of Th1 cell development, mice were intraperitoneally injected with 500 μ g of heat-killed *P. acnes*. Seven days after injection, T cells were purified from spleen and stimulated on anti-CD3 Ab (20 μ g/ml)-coated 96-well plates for 24 hr in the presence or absence of 20 ng/ml IL-18. For BCG treatment, mice were intravenously injected with 2 mg of BCG (Kyowa, Japan). T cells were purified and assayed for IFN γ production, as described above, 14 days after injection.

Transfection, Immunoprecipitation, and Western Blot Analysis

COS-7 cells (1×10^6) were transiently cotransfected with a total of 10 μ g of the indicated plasmids by Lipofection according to the manufacturer's instructions (Mirus Corporation). After 36 hr, cells were lysed in 500 μ l of lysis buffer containing 0.5% Nonidet P-40, 150 mM NaCl, 1 mM EDTA, and 10 mM Tris-HCl (pH 7.2). Half of the cell lysate was incubated with 2 μ g of anti-FLAG antibody (Eastman Kodak Company) and 40 μ l of protein-G Sepharose (Pharmacia) for 12 hr at 4°C, and the other half was incubated with 2 μ g of anti-Myc antibody (Santa Cruz) and 40 μ l of protein-A Sepharose (Pharmacia). After washing with the lysis buffer, the immunocomplex was eluted by boiling in SDS-PAGE sample buffer, separated on SDS-PAGE, and transferred onto a nitrocellulose filter. The filter was blotted with either the anti-FLAG antibody or the anti-Myc antibody and visualized using the enhanced chemiluminescence system (Dupont).

Expression Plasmids

The C-terminal FLAG-tagged human MyD88 and MyD88 (152–296) (amino acid 152 to 296) cDNAs were obtained by PCR from a human placenta cDNA library and ligated into mammalian expression vector

pEF-BOS (Mizushima and Nagata, 1990). The C-terminal Myc-tagged human IL-18R cDNA was obtained by PCR from human IL-18R cDNA as a template and ligated into pEF-BOS. Human IL-18R cDNA was kindly provided by Hayashibara Biochemical Laboratories, Inc.

Reporter Assay

COS-7 cells (1×10^6) seeded on 6-well plates were transiently cotransfected with 1.0 μ g of reporter plasmid (pNF- κ B Luc or pAP-1 Luc) (Stratagene) together with expression plasmids for IL-18R (0.4 μ g) and MyD88 (152–296) (0.6 μ g) by Lipofection. The total amounts of DNA were kept constant by supplementation with empty vector (pEF-BOS). After 24 hr of transfection, cells were stimulated with 1 μ g/ml of recombinant human IL-18 for 3 hr. The relative NF- κ B or AP-1 activity was determined and normalized on the basis of sea-pansy luciferase activity (pRL-SV40) (Promega). The recombinant human IL-18 was kindly provided by Hayashibara Biochemical Laboratories, Inc.

Gel Mobility Shift Assay

Splenic T cells were purified and cultured with 2 ng/ml IL-12 plus 100 ng/ml anti-CD3 antibody. After 4 days of culture, T cells were washed and starved with RPMI 1640 containing 2% FCS for 3 hr. Cells (1×10^7) were stimulated with 100 ng/ml IL-18 for 30 min. In the case of TNF- α -induced NF- κ B activation, freshly isolated thymocytes (1×10^7) were stimulated with 100 ng/ml TNF- α for 30 min. Cells were washed once with phosphate-buffered saline and resuspended in 400 μ l of buffer A (10 mM HEPES [pH 7.8], 10 mM KCl, 0.1 mM EDTA, 1 mM DTT, 2 μ g/ml Aprotinin, 0.5 mM PMSF, and 0.5% Triton X-100). Nuclei were pelleted, and the cytoplasmic proteins were carefully removed. The nuclei were then resuspended in buffer C (50 mM HEPES [pH 7.8], 420 mM KCl, 0.1 mM EDTA, 5 mM MgCl $_2$, 10% Glycerol, 1 mM DTT, 2 μ g/ml Aprotinin, and 0.5 mM PMSF). After vortexing and stirring for 30 min at 4°C, the samples were centrifuged, and the nuclear proteins in the supernatant were transferred to a fresh vial. Protein concentration of nuclear extracts was determined by BCA Protein Assay Reagent (Pierce). Double-stranded, NF- κ B-specific oligonucleotide probe containing two tandemly positioned NF- κ B-binding sites (5'-ATCAGGGACTTCCGCTGGGGACTTCCG-3' and 5'-GGCGAAAGTCCCCAGCGAAAGTCCTGAT-3') were labeled with [α - 32 P]dCTP by Klenow fragment. Nuclear extract (3 μ g) was incubated with a 300 fmol probe in a total of 25 μ l of binding buffer (10 mM HEPES [pH 7.8], 50 mM KCl, 1 mM EDTA, 5 mM MgCl $_2$, 10% glycerol, and 2 μ g of poly(dIdC)) for 20 min at room temperature. For the competition assay, a 50-fold molar excess of unlabeled oligonucleotide probe was added to nuclear extracts for 15 min before addition of the labeled probe. The supershift assay was performed by preincubating with 1 μ g of anti-p65 antibody (Santa Cruz) for 60 min at 4°C before addition of the labeled probe. After incubation, samples were fractionated on a 4% polyacrylamide gel in 25 mM Tris-Cl (pH 8.5), 190 mM glycine, and 1 mM EDTA. The gel was subsequently dried and visualized by autoadiography.

In Vitro Kinase Assay

Th1-developing cells prepared as described above (5×10^6) were stimulated with 100 ng/ml IL-18 for 20 min. Freshly isolated thymocytes (5×10^6) were stimulated with 100 ng/ml TNF- α for 20 min. Cells were then lysed in an ice-cold lysis buffer (20 mM Tris-Cl [pH 8.0], 137 mM NaCl, 5 mM EDTA, 10% glycerol, 1% Triton X-100, 1 mM PMSF, 20 μ g/ml Aprotinin, 20 μ g/ml Leupeptin, 1 mM Na $_2$ VO $_4$, 1 mM EGTA, 10 mM NaF, 1 mM Na $_2$ P $_2$ O $_7$, and 10 mM β -glycerophosphate). Cell lysates were precleared for 1 hr with protein A-Sepharose and then mixed with 0.5 μ g of rabbit anti-JNK1 antibody (Santa Cruz) and protein A-Sepharose for 12 hr. The beads were washed four times with the lysis buffer and once with the kinase assay buffer (25 mM HEPES [pH 7.6], 20 mM MgCl $_2$, 20 mM β -glycerophosphate, 1 mM Na $_2$ VO $_4$, and 2 mM DTT). Kinase reactions were carried out in 20 μ l of the kinase buffer containing 1 μ g of GST-c-Jun (1–79)-fusion protein (Santa Cruz) and 10 μ Ci [γ - 32 P] ATP for 30 min at 30°C. Reactions were terminated by adding 20 μ l of 2 \times SDS-PAGE sample buffer. Proteins were separated on SDS-PAGE and visualized by autoradiography.

Acknowledgments

We thank A. Maekawa for technical assistance and T. Aoki and K. Ogishi for secretarial assistance. This work was supported by grants from the Ministry of Education of Japan.

Received April 7, 1998; revised June 8, 1998.

References

- Barbulescu, K., Becker, C., Schlaak, J.F., Schmitt, E., Meyer zum Buschenfelde, K.-H., and Neurath, M.F. (1998). IL-12 and IL-18 differentially regulate the transcriptional activity of the human IFN- γ promoter in primary CD4⁺ T lymphocytes. *J. Immunol.* **160**, 3642–3647.
- Bazan, J.F., Timans, J.C., and Kastelein, R.A. (1996). A newly defined interleukin-1? *Nature* **379**, 591.
- Belvin, M.P., and Anderson, K.V. (1996). A conserved signaling pathway: the *Drosophila* toll-dorsal pathway. *Annu. Rev. Cell. Dev. Biol.* **12**, 393–416.
- Bonnert, T.P., Garka, K.E., Parnet, P., Sonoda, G., Testa, J.R., and Sims, J.E. (1997). The cloning and characterization of human MyD88: a member of an IL-1 receptor related family. *FEBS Lett.* **402**, 81–84.
- Cao, Z., Henzel, W.J., and Gao, X. (1996a). IRAK: a kinase associated with the interleukin-1 receptor. *Science* **271**, 1128–1131.
- Cao, Z., Xiong, J., Takeuchi, M., Kurama, T., and Goeddel, D.V. (1996b). TRAF6 is a signal transducer for interleukin-1. *Nature* **383**, 443–446.
- Dinarello, C.A. (1989). Interleukin-1 and its biologically related cytokines. *Adv. Immunol.* **44**, 153–205.
- Dinarello, C.A. (1996). Biologic basis for interleukin-1 in disease. *Blood* **87**, 2095–2147.
- Galindo, R.L., Edwards, D.N., Gillespie, S.K., and Wasserman, S.A. (1995). Interaction of the pelle kinase with the membrane-associated protein tube is required for transduction of the dorsoventral signal in *Drosophila* embryos. *Development* **121**, 2209–2218.
- Gay, N.J., and Keith, F.J. (1991). *Drosophila* Toll and IL-1 receptor. *Nature* **351**, 355–356.
- Ghayur, T., Banerjee, S., Hugunier, M., Butler, D., Herzog, L., Carter, A., Quintal, L., Sekut, L., Talanian, R., Paskind, M., et al. (1997). Caspase-1 processes IFN- γ inducing factor and regulates LPS-induced IFN- γ production. *Nature* **386**, 619–623.
- Greenfeder, S.A., Nunes, P., Kwee, L., Labow, M., Chizzonite, R.A., and Ju, G. (1995). Molecular cloning and characterization of a second subunit of the interleukin 1 receptor complex. *J. Biol. Chem.* **270**, 13757–13765.
- Grosshans, J., Bergmann, A., Haffter, P., and Nusslein-Volhard, C. (1994). Activation of the kinase Pelle by Tube in the dorsoventral signal transduction pathway of *Drosophila* embryo. *Nature* **372**, 563–566.
- Gu, Y., Kuida, K., Tsutsui, H., Ku, G., Hsiao, K., Fleming, M.A., Hayashi, N., Higashino, K., Okamura, H., Nakanishi, K., et al. (1997). Activation of interferon- γ inducing factor mediated by interleukin-1 β converting enzyme. *Science* **275**, 206–209.
- Hardiman, G., Rock, F.L., Balasubramanian, S., Kastelein, R.A., and Bazan, J.F. (1996). Molecular characterization and molecular analysis of human MyD88. *Oncogene* **13**, 2467–2475.
- Hashimoto, C., Hudson, K.L., and Anderson, K.V. (1988). The Toll gene of *Drosophila*, required for dorsal-ventral embryonic polarity, appears to encode a transmembrane protein. *Cell* **52**, 269–279.
- Huang, J., Gao, X., Li, S., and Cao, Z. (1997). Recruitment of IRAK to the interleukin-1 receptor complex requires interleukin-1 receptor accessory protein. *Proc. Natl. Acad. Sci. USA* **94**, 12829–12832.
- Hultmark, D. (1994). Macrophage differentiation marker MyD88 is a member of the Toll/IL-1 receptor family. *Biochem. Biophys. Res. Commun.* **199**, 144–146.
- Korherr, C., Hofmeister, R., Wesche, H., and Falk, W. (1997). A critical role for interleukin-1 receptor accessory protein in interleukin-1 signaling. *Eur. J. Immunol.* **27**, 262–267.
- Lemaitre, B., Nicolas, E., Michaut, L., Reichhart, J.M., and Hoffmann, J.A. (1996). The dorsoventral regulatory gene cassette *spatzle/toll* controls the potent antifungal response in *Drosophila* adults. *Cell* **86**, 973–983.
- Letsou, A., Alexander, S., and Wasserman, S.A. (1993). Domain mapping of tube, a protein essential for dorsoventral patterning of the *Drosophila* embryo. *EMBO J.* **12**, 3449–3458.
- Lord, K.A., Hoffman-Liebermann, B., and Liebermann, D.A. (1990). Nucleotide sequence and expression of a cDNA encoding MyD88, a novel myeloid differentiation primary response gene induced by IL-6. *Oncogene* **5**, 1095–1097.
- Lovenberg, T.W., Croue, P.D., Liu, C., Chalmers, D.T., Liu, X.J., Liaw, C., Clevenger, W., Oltersdorf, T., de Souza, E.B., and Maki, R.A. (1996). Cloning of a cDNA encoding a novel interleukin-1 receptor related protein (IL-1R-rp2). *J. Neuroimmunol.* **70**, 113–122.
- Mannel, D.A., Mizel, S.B., Diamanstein, T., and Falk, W. (1985). Induction of interleukin 2 responsiveness in thymocytes by synergistic action of interleukin 1 and interleukin 2. *J. Immunol.* **134**, 3108–3110.
- Matsui, K., Yoshimoto, T., Tsutsui, H., Hyodo, Y., Hayashi, N., Hiroishi, K., Kawada, N., Okamura, H., Nakanishi, K., and Higashino, K. (1997). Propionibacterium acnes treatment diminishes CD4⁺NK1.1⁺ T cells but induces type 1 T cells in the liver by induction of IL-12 and IL-18 production from Kupffer cells. *J. Immunol.* **159**, 97–106.
- Matsumoto, S., Tsuji-T, K., Aizawa, Y., Koide, K., Takeuchi, M., Ohta, T., and Kurimoto, M. (1997). Interleukin-18 activates NF- κ B in murine T helper type 1 cells. *Biochem. Biophys. Res. Commun.* **234**, 454–457.
- Medzhitov, R., and Janeway, C.A., Jr. (1997). Innate Immunity: the virtues of a nonclonal system of recognition. *Cell* **91**, 295–298.
- Medzhitov, R., Preston-Hurlburt, P., and Janeway, C.A., Jr. (1997). A human homologue of the *Drosophila* Toll protein signals activation of adaptive immunity. *Nature* **388**, 394–397.
- Mitcham, J.L., Parnet, P., Bonnert, T.P., Garka, K.E., Gerhart, M.J., Slack, J.L., Gayle, M.A., Dower, S.K., and Sims, J.E. (1996). T1/ST2 signaling establishes it as a member of an expanding interleukin-1 receptor family. *J. Biol. Chem.* **271**, 5777–5783.
- Mizushima, S., and Nagata, S. (1990). pEF-BOS, a powerful mammalian expression vector. *Nucleic Acids Res.* **18**, 5322.
- Morisato, D., and Anderson, K.V. (1994). The *spatzle* gene encodes a component of the extracellular signaling pathway establishing the dorsal-ventral pattern of the *Drosophila* embryo. *Cell* **76**, 677–688.
- Morisato, D., and Anderson, K.V. (1995). Signaling pathways that establish the dorso-ventral pattern of the *Drosophila* embryo. *Annu. Rev. Genet.* **29**, 371–399.
- Muzio, M., Ni, J., Feng, P., and Dixit, V.M. (1997). IRAK (Pelle) family member IRAK-2 and MyD88 as proximal mediators of IL-1 signaling. *Science* **278**, 1612–1615.
- Norris, J.L., and Manley, J.L. (1996). Functional interaction between the pelle kinase, Toll receptor, and tube suggest a mechanism for activation of dorsal. *Genes Dev.* **10**, 862–872.
- Okamura, H., Nagata, K., Komatsu, T., Tanimoto, T., Nukata, Y., Tanabe, F., Akita, K., Torigoe, K., Okura, T., Fukuda, S., et al. (1995a). A novel costimulatory factor for gamma interferon induction found in the livers of mice causes endotoxin shock. *Infect. Immun.* **63**, 3966–3972.
- Okamura, H., Tsutsui, H., Komatsu, T., Yutsudo, M., Hakura, A., Tanimoto, T., Torigoe, K., Okura, T., Nukada, Y., Hattori, K., et al. (1995b). Cloning of a new cytokine that induces IFN- γ production by T cells. *Nature* **378**, 88–91.
- Parnet, P., Garka, K.E., Bonnert, T.P., Dower, S.K., and Sims, J.E. (1996). IL-1Rrp is a novel receptor-like molecule similar to the type I interleukin-1 receptor and its homologues T1/ST2 and IL-1R AcP. *J. Biol. Chem.* **271**, 3967–3970.
- Robinson, D., Shibuya, K., Mui, A., Zonin, F., Murphy, E., Sana, T., Hartley, S.B., Menson, S., Kastelein, R., Bazan, F., and O'Garra, A. (1997). IGIF does not drive Th1 development but synergizes with IL-12 for interferon- γ production and activates IRAK and NF- κ B. *Immunity* **7**, 571–581.
- Rock, F.L., Hardiman, G., Timans, J.C., Kastelein, R.A., and Bazan, J.F. (1998). A family of human receptors structurally related to *Drosophila* Toll. *Proc. Natl. Acad. Sci. USA* **95**, 588–593.

- Shelton, C.A., and Wasserman, S.A. (1993). *pelle* encodes a protein kinase required to establish dorsoventral polarity in the *Drosophila* embryo. *Cell* 72, 515–525.
- Suda, T., Hodgkin, P., Lee, F., and Zlotnik, A. (1989). Biological activity of recombinant murine interleukin 6 in interleukin 1 T cell assays. *J. Immunol. Methods* 120, 173–178.
- Takeda, K., Tsutsui, H., Yoshimoto, T., Adachi, O., Yoshida, N., Kishimoto, T., Okamura, H., Nakanishi, K., and Akira, S. (1998). Defective NK cell activity and Th1 response in IL-18-deficient mice. *Immunity* 8, 383–390.
- Torigoe, K., Ushio, S., Okura, T., Kobayashi, S., Tanai, M., Kunikata, T., Murakami, T., Sanou, O., Kojima, H., Fujii, M., et al. (1997). Purification and characterization of the human interleukin-18 receptor. *J. Biol. Chem.* 272, 25737–25742.
- Tsutsui, H., Nakanishi, K., Matsui, K., Higashino, K., Okamura, H., Miyazawa, Y., and Kaneda, K. (1996). IFN- γ -inducing factor up-regulates Fas ligand-mediated cytotoxic activity of murine natural killer cell clones. *J. Immunol.* 157, 3967–3973.
- Ushio, S., Namba, M., Okura, T., Hattori, K., Nukada, Y., Akita, K., Tanabe, F., Konishi, K., Micallef, M., Fujii, M., et al. (1996). Cloning of the cDNA for human IFN- γ inducing factor, expression in *Escherichia coli* and studies on the biologic activities of the protein. *J. Immunol.* 156, 4274–4279.
- Wasserman, S.A. (1993). A conserved signal transduction pathway regulating the activity of the rel-like proteins dorsal and NF- κ B. *Mol. Biol. Cell* 4, 767–771.
- Wesche, H., Korherr, C., Kracht, M., Falk, W., Resch, K., and Martin, M.U. (1997a). The interleukin-1 receptor accessory protein (IL-1RAcP) is essential for IL-1-induced activation of interleukin-1 receptor associated kinase (IRAK) and stress-activated protein kinases (SAP kinases). *J. Biol. Chem.* 272, 7727–7731.
- Wesche, H., Henzel, W.J., Shillinglaw, W., Li, S., and Cao, Z. (1997b). MyD88: an adaptor that recruits IRAK to the IL-1 receptor complex. *Immunity* 7, 837–847.
- Yanagisawa, K., Takagi, T., Tsukamoto, T., Tetsuka, T., and Tomimaga, S. (1993). Presence of a novel primary response gene ST2L, encoding a product highly similar to the interleukin 1 receptor type 1. *FEBS Lett.* 318, 83–87.